Protagonist Therapeutics Stock (NASDAQ: PTGX)

Protagonist Therapeutics

PROTAGONIST THERAPEUTICS INC

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Johnson & Johnson Inc. JNJ

Biotech

Large Cap

News

Health Care

General

PTGX

UCBJF

UCBJY

Protagonist and J&amp;J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

Protagonist/Johnson &amp; Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

Protagonist and Johnson &amp; Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.

Johnson &amp; Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study

D-Wave Quantum Inc.

Equities

Mid Cap

Movers

Trading Ideas

HSAI

IONQ

ORLA

QBTS

RGTI

SMTC

Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains.

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics Inc

Press Releases

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

Earnings

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

TYO:4502

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

ImmunityBio

Immunovant

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Vericel

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Comments

Protagonist Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell